Models are presented for we in assessing genetic susceptibility to cancer (or other diseases) with animal or human data.
Introduction
Recent technological advances in biomedical experimentation have greatly improved identification of genetic damage (1) and recognition of genetic factors that may affect disease susceptibilities in animal (2) and human (3) subjects. Molecular genetic techniques are now used to idenitify specific genotypes or genetic patterns in individuals affected by some disease or, for example, exhibiting cancer. For instance, the role ofgenetic factors in lung tumor onset and progression has been recently highlighted (4) (5) (6) (7) , as have genetic components in the development ofhuman bladder tumors and other cancers (8) (9) (10) . To study these effects, various biochemical, cytogenetic, and molecular probes are used (11) (12) (13) (14) , and epidemiologic research has moved to use these methods in studies ofdisease/cancer susceptibility (15, 16) . Of interest is whether individuals in various genetic categories display greater risk of cancer or disease than those identified in some background, control, or genetic "wild-type" category. Statistical models and methods for assessing these risks in both animal experiments and human population studies are described in the following sections.
Statistical Models: Generalized Linear Forms
Assume the existence of T>2 genetic susceptibility groups or categories, identified without error via some form ofbiological/ biomolecular probe, and indexed by i=O,. . ., T-1. For instance, the experimental study design might compare the effects of Statistics 
Example 1
To illustrate use of the logistic model in Equation 1, consider the lung tumor susceptibility data given by Ryan et al. (4) . These authors considered susceptibility to the known murine carcinogen urethan by examining specific allelic forms of the Kras-2 proto-oncogene in recombinant offspring from crosses of inbred strains of mice. The susceptibility allele is characterized by a shorter initial exon (length 0.55 kb) compared to the normal allele (length 0.70 kb). The mice under study were known to be either homozygous for the 0.70-kb allele, or heterozygous (0.70 kb/0.55 kb). Ifthe 0.55-kb allele were to confer or otherwise indicate increased susceptibility to lung tumorigenesis, heterozygous mice would exhibit greater lung tumor rates and thus an odds ratio relative to the homozygous mice greater than one.
The data for the T=2 groups are shown in Table 1 For these data, this yields 1.14 <461 <106. 45 .
Based on this analysis, it seems fair to conclude that the 0.70-kb/0.55-kb heterozygous genotype exhibited moderately increased risk of murine lung tumorigenesis relative to the homozygous genotype. Sample sizes are small; total samples of at least 100 have been suggested to achieve nominal operating characteristics in one-sided testing under the logistic model (24 Consider the case oftwo factors: the genetic factor continues to be indexed by i=0,..., T-1, and an additional, "environmental" factor is now considered, indexed by j=O,...,J-1. The associated two-way extension of Equation 1 takes the T x J form log {1 } = + j + Yij (2) (i=O,...,T-l; j=0,.. .,J-1). As 
Applications in Epidemiology
Once a potential susceptibility gene has been identified in humans, its association with disease can be tested in epidemiologic population studies using case-control study designs (33) . Sampling in a case-control study is carried out separately for cases and controls in a retrospective manner and thus in effect is conditioned on disease status (34) . As is well known, however, one can reverse this conditioning and model the logit of the risk ofdisease as a function ofcovariates as in Equation 1 or 2, treating the data as if they had arisen prospectively. The resulting regression coefficients are asymptotically unbiased for the associated log odds ratios (35, 36) , and likelihood ratio testing based on the prospective logistic model is valid when applied to case-control data (37) . Thus the (prospective) logistic models descibed above are applicable in retrospective (and prospective) epidemiologic studies where genetic susceptibility is under examination. In a case-control study, Caparaso et al. (38) examined individual subjects' abilities to metabolize the drug debrisoquine and related these metabolic activities to lung cancer susceptibility. Increased ability to metabolize agents such as debrisoquine is conjectured to indicate increased cancer susceptibility because heterogenity in drug metabolism may associate with heterogeneity in cancer susceptibility. (For example, the drug metabolism pathway may play a role in carcinogenesis metabolism, either by deactivating a carcinogen or by activating a proto-carcinogen into a carcinogen.) Debrisoquine metabolism is polymorphic in humans: most individuals receiving the drug rapidly excrete large amounts ofdebrisoquine metabolite (39); these individuals are "extensive metabolizers" (EM). Some individuals excrete reduced amounts ofthe metabolite or excrete the drug almost unchanged. They are "intermediate" (IM) or "poor" metabolizers (PM), respectively (5). These polymorphisms lead to T=3 genetic categories for study.
An initial question of interest is whether the intermediate or poor metabolizers truly constitute two distinct genetic classes with respect to their lung cancer susceptibility. That is, is collapsibility evidenced between PM and IM? To study this question, Caporaso et al. (38) reported the case-control data shown in Table 2 . Since the logistic model is applicable to this retrospective sampling scenario (37), we consider the prospective form in Equation I to model the genetic effects. As suggested above, collapsibility ofPM and IM categories corresponds to equality of main effects parameters: Ho:ca=a=2. To 
Data Truncation
In some settings, the experimental end point may involve the number of occurrences of some phenomenon, such as the number of tumors seen in a certain organ of an experimental animal (40) or the number ofcells in a tissue or culture responding to a chemical stimulus (41) . Denote the random variable associated with this discrete-valued response by U. Ifthe observing mechanism or technique is such that only the occurrence of a non-null state is recorded (e.g., "no tumors" versus "some tumors"), the data will be truncated into a dichotomous response. 
